



7-30-04

IFW

Please type a plus sign (+) inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/789,102
		Filing Date	February 27, 2004
		First Named Inventor	LU, PETER S.
		Group Art Unit	1644
		Examiner Name	
Total Number of Pages in This Submission	4 + refs.	Attorney Docket Number	VITA-009
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08A 2. Copy of cited references 3. Postcard	Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	JAMES S. KEDDIE, PH.D., 48,920 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	July 28, 2004		
EXPRESS MAIL LABEL NO. EV462737281US			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV462737281US

INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	VITA-009
	First Named Inventor	LU, PETER S.
	Application Number	10/789,102
	Confirmation No.	8072
	Filing Date	February 27, 2004
	Group Art Unit	1644
	Examiner Name	
Title: "METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER"		

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.


As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. VITA-009 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: July 28, 2004

By: 
James S. Keddie, Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/789,102
				Filing Date	February 27, 2004
				First Named Inventor	LU, PETER S.
				Art Unit	1644
Sheet	1	of	2	Examiner Name	
				Attorney Docket Number	VITA-009

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US- 4,777,239		10-11-1988	Schoolnik, et al.	
		US- 5,204,061		04-20-04	Covington, et al.	
		US- 5,415,995		05-16-95	Schoolnik, et al.	
		US- 5,648,459		07-15-97	Cole, et al.	
		US- 5,665,535		09-09-97	Orth, et al.	
		US- 5,747,274		05-05-98	Jackowski, et al.	
		US- 5,753,233		05-19-98	Bleul, et al.	
		US- 5,876,723		03-02-99	Cole, et al.	
		US- 6,322,794		11-27-01	Bleul, et al.	
		US- 6,344,314		02-05-02	Cole, et al.	
		US- 5,610,077		03-11-97	Davis, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		GARDIOL et al., MUTATIONAL ANALYSIS OF THE DISCS LARGE TUMOUR SUPPRESSOR IDENTIFIES DOMAINS RESPONSIBLE FOR HUMAN PAPILOMAVIRUS TYPE 18 E6-MEDIATED DEGRADATION, Journal of General Virology, 2002, 83: 283-289	
		GLAUNSINGER et al., INTERACTIONS OF THE PDZ-PROTEIN MAGI-1 WITH ADENOVIRUS E4-ORF1 AND HIGH-RISK PAPILOMAVIRUS E6 ONCOPROTEINS, Oncogene, (2000), 19:5270-80	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/789,102		
		Filing Date	February 27, 2004		
		First Named Inventor	LU, PETER S.		
		Art Unit	1644		
Sheet	2	of	2	Examiner Name	
				Attorney Docket Number	VITA-009

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		GUIOT et al., IMMUNOLOGICAL DETECTION OF E6 REGION PROTEIN FROM HUMAN PAPILLOMAVIRUS TYPES 16 AND 18 IN PREMALIGNANT CERVICAL LESIONS, Cancer Cells, 1989, 7: 193-196	
		KIYONO et al., BINDING OF HIGH-RISK HUMAN PAPILLOMAVIRUS E6 ONCOPROTEINS TO THE HUMAN HOMOLOGUE OF THE DROSOPHILA DISCS LARGE TUMOR SUPPRESSOR PROTEIN, Proc. Natl. Acad. Sci., (1997), 94:11612-6	
		LEE et al., BINDING OF HUMAN VIRUS ONCOPROTEINS TO HDLG/SAP97, A MAMMALIAN HOMOLOG OF THE DROSOPHILA DISCS LARGE TUMOR SUPPRESSOR PROTEIN, Proc. Natl. Acad. Sci., (1997), 94:6670-5	
		MATHUR et al., HUMAN PAPILLOMAVIRUS (HPV)-E6/E7 AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGF-R) PROTEIN LEVELS IN CERVICAL CANCER AND CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN), American Journal of Re. Immun., 2001, 46(4): 280-287	
		MESCHEDE et al., ANTIBODIES AGAINST EARLY PROTEINS OF HUMAN PAPILLOMAVIRUSES AS DIAGNOSTIC MARKERS FOR INVASIVE CERVICAL CANCER, J. Clin. Microbiol., (1998), 36:475-80	
		MUNGER et al., THE ROLE OF HUMAN PAPILLOMAVIRUSES IN HUMAN CANCERS, Front. Biosci., (2002), 7:d641-9	
		PIM et al., HPV-18 E6*1 PROTEIN MODULATES THE E6-DIRECTED DEGRADATION OF P53 BY BINDING TO FULL-LENGTH HPV-18 E6, Oncogene, (1999), 18:7403-8	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.